Postoperative pulmonary complications (atelectasis and pneumonia) in the ENIGMA 2 Trial

Austin Health0 sites2,325 target enrollmentFebruary 15, 2022

Overview

No summary available.

Registry

who.int

Start Date

February 15, 2022

End Date

TBD

Last Updated

4 years ago

Study Type

Observational

Sex

All

Sponsor

•Participants randomised to the ENIGMA 2 Trial within Australia, according to the ENIGMA 2 inclusion criteria:
•Adult males and females age \>/\= 45 years, undergoing noncardiac surgery and general anaesthesia expected to exceed two hours.
•At increased risk of cardiac events, defined as any of
•history of coronary artery disease as defined by a history of any one of the following: i. angina ii. MI iii. segmental wall motion abnormality on echocardiography or a fixed defect on radionuclide imaging iv. a positive exercise stress test for cardiac ischaemia v. a positive radionuclide exercise, echocardiographic exercise, or pharmacological cardiovascular stress test for cardiac ischaemia vi. coronary revascularization (CABG or PTCA) vii. angiographic evidence of atherosclerotic stenosis \> 50% of the diameter of any coronary artery viii. ECG with pathological Q waves in two contiguous leads
•heart failure
•cerebrovascular disease thought due to atherothrombotic disease
•aortic or peripheral vascular disease
•or three or more of the following risk factors:
•age \>/\=70 years
•any history of congestive heart failure

•having cardiac surgery
•marked impairment of gas\-exchange expected to require Fi02\> 0\.5 intraoperatively
•specific circumstances where N2O is contraindicated (eg. volvulus, pulmonary hypertension, raised intracranial pressure) or the anaesthetist plans to use supplemental oxygen (eg. colorectal surgery)
•N2O unavailable for use.